Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-based model: extended follow-up of a phase II trial.

In myeloma, achievement of very good partial response (VGPR) post-transplant is associated with prolonged overall (OS) and progression-free survival (PFS). In this study of bortezomib, pegylated liposomal doxorubicin, and dexamethasone (VDD) in 40 patients with newly diagnosed myeloma (median follow-up 45.1 months), 2-/4-year OS estimates were 95.7%/86.5% versus 82.4%/58.2% for patients achieving ≥VGPR versus 

Keywords:

• Pegylated Liposomal Doxorubicin
• Free Light Chain
• Diabetes mellitus
• Bortezomib
• Dexamethasone
• Immunology
• Medicine
• Very Good Partial Response
• Myeloma protein
• initial treatment
• overall survival

• Correction
• Source
• Cite
• Save
• Machine Reading By IdeaReader